查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1995463

類固醇注射市場：按分子類型、治療類型、患者類型、適應症、最終用戶和分銷管道分類－2026-2032年全球市場預測

Steroid Injections Market by Molecule Type, Treatment Type, Patient Type, Therapeutic Indication, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 199 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，類固醇注射劑市場價值將達到 57.2 億美元，到 2026 年將成長至 62 億美元，到 2032 年將達到 103.9 億美元，複合年成長率為 8.90%。

主要市場統計數據
基準年 2025 57.2億美元
預計年份：2026年 62億美元
預測年份：2032年 103.9億美元
複合年成長率 (%) 8.90%

對塑造現代類固醇注射實踐和廣泛應用的臨床、營運和監管環境進行了權威概述。

皮質類固醇注射在介入治療和保守治療之間發揮橋樑作用，在現代疼痛管理和肌肉骨骼疾病治療中佔據核心地位。皮質類固醇注射仍是臨床醫生治療發炎性疾病、急性發作以及關節、軟組織和脊椎腔內特定部位疼痛的主要治療方法。近年來，隨著療效比較數據的累積、對標靶給藥的日益重視以及影像引導技術的應用，臨床實踐不斷發展，以提高注射的準確性和安全性。

精準給藥、供應鏈韌性和支付方主導的證據要求方面的進步，如何從整體上重塑類固醇注射的實踐和商業化？

目前，類固醇注射療法正經歷著一場變革性的轉變，這主要得益於臨床技術的進步、供應鏈的重組以及支付者期望的改變。在臨床方面，包括超音波和透視引導在內的精準注射方法正在加速普及，從而提高了標靶準確性並減少了手術相關併發症。同時，疼痛專科醫生、骨科醫生和介入放射科醫生之間的培訓項目不斷加強，跨學科合作也日益普及。此外，以患者為中心的治療路徑也越來越受到重視，這些路徑將注射治療與康復、藥物治療最佳化以及患者參與決策相結合。

近期關稅變化對營運和商業產生了哪些影響？採購、製造和分銷領域的相關人員如何調整以維持供應的連續性？

2025年實施的關稅措施進一步增加了參與類固醇注射療法相關醫療產品生產、分銷和採購的相關人員的複雜性。進口關稅和雙邊貿易措施的變化可能會影響活性成分、輔料和手術醫療設備的成本基礎，促使製造商重新評估與供應商的合約並探索近岸外包的機會。因此，採購團隊和對採購敏感的設施越來越關注總到岸成本、前置作業時間波動和供應商多元化，以降低與貿易相關的價格波動風險。

根據細分市場分析制定目標策略，該分析能夠解讀分子選擇標準、治療背景、患者人口統計特徵、治療適應症、醫療環境和分銷管道。

精準的市場區隔對於協調類固醇注射的臨床開發、商業策略和分銷計劃至關重要。從分子類型來看，此細分市場包括地塞米松、Hydrocortisone、Methylprednisolone和曲安奈德等藥物，每種藥物都具有其獨特的效力、作用持續時間和安全性，這些因素會影響臨床選擇和製劑定位。治療類型細分則明確了關節注射、軟組織注射和脊椎注射等手術的具體情況。關節注射進一步分為大關節和小關節；軟組織注射再細分為滑囊注射、韌帶注射和肌腱注射；脊椎注射則分為硬脊膜外注射和鞘內注射。這些區分反映了特定操作的訓練要求、醫療設備需求以及報銷代碼的細微差別。

影響臨床實踐模式、監管方法和供應鏈策略的美洲、歐洲、中東和非洲以及亞太地區的區域趨勢。

區域趨勢對類固醇注射的臨床實踐模式、監管預期和商業性策略有顯著影響。在美洲，成熟的門診基礎設施、微創疼痛管理計畫的高普及率以及支付方對治療效果和合理使用的嚴格審查，共同塑造了該療法的應用。美洲內部的跨境貿易和採購關係也影響籌資策略，並可能創造建立區域製造地的機會，從而縮短前置作業時間並降低關稅風險。

深入了解製藥公司、醫療設備創新者和服務供應商如何整合證據、供應鏈彈性和綜合解決方案，以有效參與競爭。

類固醇注射產品和服務的競爭格局由成熟的製藥公司、支援手術操作的醫療設備供應商以及在臨床環境中提供解決方案和培訓的專業服務機構組成。領先的製藥企業優先考慮透過改進配方、確保穩定供應和驗證臨床安全性來實現產品組合的差異化。同時，醫療設備製造商也在推動藥物輸送系統和影像引導相容性方面的創新，以提高手術的精準度和工作流程的效率，從而為滿足製藥和醫療設備雙方需求的捆綁式解決方案創造了機會。

製造商和供應商可採取的策略重點是加強證據產生、實現供應鏈多元化以及建構綜合治療和給藥解決方案。

為了在類固醇注射劑領域保持長期競爭力，產業領導企業必須採取積極主動的策略，協調臨床證據的產生、供應鏈策略和商業性執行。首先，各企業應優先投資於真實世界資料（RWE）計畫和上市後監測，以揭示不同適應症和給藥途徑下相對安全有效的療效。這些證據將有助於製定藥物採納清單、與支付方進行談判以及推動臨床醫生採納，同時也指南產品的持續改進。

為了得出確切的結論，我們採用了一種透明的混合方法研究途徑，結合了對臨床醫生的訪談、採購方面的見解、監管審查和文獻整合。

本分析的調查方法融合了定性和定量方法，旨在全面了解臨床實踐、供應動態和商業性促進因素。主要研究包括對常規注射類固醇的專科臨床醫生、醫院和門診中心的採購經理以及生產和分銷公司的管理人員進行結構化訪談。這些訪談提供了關於手術量、臨床醫生對藥物分子和給藥方法的偏好以及與庫存和採購相關的營運挑戰的第一手資訊。

一項權威性的綜合分析強調了臨床價值、供應韌性和跨部門策略是未來提供類固醇注射護理成功的決定因素。

總之，類固醇注射仍然是肌肉骨骼和疼痛管理實踐中不可或缺的一部分，這得益於技術創新、精準的臨床應用以及高度靈活的給藥模式。相關人員面臨著日益重視精準給藥、支付方對主導醫學的期望以及潛在的供應鏈壓力（包括貿易相關的成本波動）等諸多挑戰。因此，強調可靠的真實世界證據、多元化的採購管道以及整合的產品和服務交付的策略應對措施，被認為是滿足臨床醫生和醫療機構需求並保持營運韌性的關鍵。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 工業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：類固醇注射市場：依分子類型分類

  • 地塞米松
  • Hydrocortisone
  • Methylprednisolone
  • 曲安奈德

第9章：類固醇注射市場：依治療類型分類

  • 關節注射
    • 大關節
    • 小關節
  • 注射到軟組織
    • 滑囊注射
    • 韌帶注射
    • 肌腱內注射
  • 脊椎注射
    • 硬脊膜外麻醉
    • 鞘內腔

第10章：類固醇注射市場：依病患類型分類

  • 成人
  • 老年人
  • 兒童

第11章：類固醇注射市場：依適應症分類

  • 腰痛
    • 腰痛
    • 坐骨神經痛
    • 上背部疼痛
  • 黏液囊炎
  • 骨關節炎
  • 類風濕性關節炎
  • 肌腱炎

第12章：類固醇注射市場：依最終用戶分類

  • 門診手術中心
  • 診所
  • 醫院
    • 綜合醫院
    • 專科醫院

第13章：類固醇注射市場：依通路分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房
    • 連鎖藥局
    • 獨立經營藥房

第14章：類固醇注射市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章：類固醇注射市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章：類固醇注射市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章：美國注射類固醇市場

第18章：中國注射類固醇市場

第19章 競爭情勢

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • AbbVie Inc.
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Roche Holding AG
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
Product Code: MRR-4103B31E091F

The Steroid Injections Market was valued at USD 5.72 billion in 2025 and is projected to grow to USD 6.20 billion in 2026, with a CAGR of 8.90%, reaching USD 10.39 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 5.72 billion
Estimated Year [2026] USD 6.20 billion
Forecast Year [2032] USD 10.39 billion
CAGR (%) 8.90%

An authoritative introduction to the clinical, operational, and regulatory landscape shaping contemporary steroid injection practice and procedural adoption

Steroid injections occupy a central role in contemporary pain management and musculoskeletal care, bridging interventional treatment and conservative therapies. Corticosteroid injections remain a mainstay for clinicians managing inflammatory conditions, acute exacerbations, and targeted pain relief across joints, soft tissues, and spinal spaces. Over recent years, clinical practice has evolved in response to accumulating comparative effectiveness data, a greater emphasis on targeted delivery, and the integration of image-guided techniques that enhance precision and safety.

Clinicians and hospital systems have adapted procedural pathways to balance efficacy, patient safety, and operational throughput. Concurrently, regulatory scrutiny and payer engagement have influenced procedural adoption by foregrounding outcomes, safety profiles, and appropriate use criteria. The combination of technological refinements, heightened demand for minimally invasive interventions, and an aging population with chronic musculoskeletal conditions has kept steroid injections in active clinical use while stimulating continued innovation in formulations, delivery systems, and procedural protocols. This introduction frames the subsequent analysis by situating steroid injections within a dynamic clinical, commercial, and regulatory ecosystem.

How advances in precision delivery, supply chain resilience, and payer-driven evidence requirements are collectively reshaping steroid injection practice and commercialization

The landscape for steroid injections is undergoing transformative shifts driven by converging clinical advances, supply chain realignments, and shifting payer expectations. Clinically, there is an accelerating adoption of precision approaches, including ultrasound and fluoroscopy guidance, which improve targeting and reduce procedure-related complications; this trend is complemented by enhanced training programs and cross-disciplinary collaboration between pain specialists, orthopedists, and interventional radiologists. Moreover, there is heightened attention to patient-centered care pathways that integrate injection therapy with rehabilitation, pharmacologic optimization, and shared decision-making.

On the supply chain front, manufacturers and distributors have responded to raw material constraints, logistics challenges, and regulatory changes by diversifying sourcing strategies and investing in regional manufacturing resilience. In parallel, health systems have intensified evaluations of procedural value, requesting stronger evidence for comparative effectiveness and longer-term outcome measures, thereby prompting manufacturers to focus on real-world evidence generation and payer engagement. Technological innovation extends beyond imaging to include targeted-release formulations and delivery adjuncts that seek to extend symptom relief while minimizing systemic exposure. Taken together, these shifts are reshaping how steroid injections are developed, delivered, and reimbursed, creating new imperatives for stakeholders to adapt commercial models and clinical protocols.

Operational and commercial repercussions of recent tariff changes and how procurement, manufacturing, and distribution stakeholders are adapting to maintain supply continuity

Tariff policies enacted in 2025 have introduced an additional layer of complexity for stakeholders involved in the manufacture, distribution, and procurement of medical products related to steroid injection therapy. Changes in import duties and bilateral trade measures have the potential to affect the cost base for active pharmaceutical ingredients, excipients, and medical devices used in procedural delivery, prompting manufacturers to reassess supplier contracts and to explore nearshoring opportunities. As a result, procurement teams and procurement-sensitive facilities have heightened their focus on total landed cost, lead-time variability, and supplier diversification to mitigate exposure to trade-related price shocks.

In response to tariff-induced pressures, several strategic responses have emerged across the value chain. Manufacturers have accelerated assessments of alternative sourcing jurisdictions and have revisited inventory policies to balance working capital considerations against the risk of supply disruptions. Distributors and hospital systems have adjusted contracting frameworks to incorporate tariff pass-through clauses and more flexible procurement terms. At the same time, regulatory authorities and industry associations have engaged in dialogue to clarify classification and duty treatments for complex pharmaceutical products and combination devices. While tariffs have not changed clinical indications or practitioner decision-making directly, they have catalyzed operational and commercial adaptations that influence pricing strategies, supply continuity planning, and the pace of product innovation.

Segment-by-segment analysis that decodes molecule preferences, procedural contexts, patient demographics, therapeutic indications, care settings, and distribution pathways for targeted strategy

A nuanced understanding of market segmentation is essential to align clinical development, commercial strategy, and distribution planning for steroid injections. When considering molecule types, the field encompasses agents such as dexamethasone, hydrocortisone, methylprednisolone, and triamcinolone, each with distinct potency profiles, duration of action, and safety considerations that influence clinical selection and formulary positioning. Treatment type segmentation delineates procedural contexts including joint injections, soft tissue injections, and spinal injections, with joint injections further differentiated by large joints and small joints, soft tissue injections subdivided into bursa injections, ligament injections, and tendon injections, and spinal injections differentiated into epidural and intrathecal procedures; these differentiations reflect procedure-specific training requirements, device needs, and reimbursement coding nuances.

Patient type segmentation-adult, geriatric, and pediatric-imposes important variations in dosing strategies, safety monitoring, and clinical outcomes, with geriatric patients often presenting comorbidities that influence therapeutic choice and follow-up protocols. Therapeutic indication segmentation covers conditions such as back pain, bursitis, osteoarthritis, rheumatoid arthritis, and tendonitis, and back pain is further analyzed across lower back pain, sciatica, and upper back pain; these indication-level distinctions inform trial design, outcome metrics, and the expected duration of symptom relief sought by clinicians and patients. End-user segmentation identifies ambulatory surgical centers, clinics, and hospitals as the primary delivery settings, with hospitals further categorized into general hospitals and specialty hospitals, reflecting differences in procedural volume, inpatient integration, and credentialing requirements. Distribution channel segmentation highlights hospital pharmacies, online pharmacies, and retail pharmacies, and retail pharmacies are further divided into chain pharmacies and independent pharmacies, indicating distinct procurement behaviors, inventory management capabilities, and contractual dynamics. Synthesizing these segmentation layers reveals differentiated commercialization pathways, targeted evidence requirements, and bespoke distribution strategies that manufacturers and service providers must design to meet the clinical and operational realities of each segment.

Regional dynamics across the Americas, Europe Middle East & Africa, and Asia-Pacific that influence clinical practice patterns, regulatory approaches, and supply chain strategies

Regional dynamics exert a strong influence on clinical practice patterns, regulatory expectations, and commercial approaches for steroid injections. In the Americas, procedural utilization is shaped by a mature outpatient infrastructure, a high prevalence of minimally invasive pain management programs, and payer scrutiny that emphasizes outcomes and appropriate use. Cross-border trade and procurement relationships within the Americas also influence sourcing strategies and can create opportunities for regional manufacturing hubs that reduce lead times and tariff exposure.

The Europe, Middle East & Africa region presents a heterogeneous landscape where regulatory frameworks, reimbursement systems, and clinical practice traditions vary significantly across countries. This diversity encourages differentiated market access approaches, with some jurisdictions prioritizing stringent evidence packages while others adopt pragmatic reimbursement models that favor procedural adoption in ambulatory and specialized settings. Meanwhile, the Asia-Pacific region is characterized by rapid expansion of outpatient procedural capacity, growing investment in clinical training and imaging infrastructure, and a dynamic mix of local manufacturers and multinational entrants. Across regions, stakeholders must navigate local regulatory nuances, clinical practice patterns, and supply chain configurations to effectively deploy products and services, and regional partnerships or manufacturing investments can materially influence speed to market and operational resilience.

Insights into how pharmaceutical manufacturers, device innovators, and service providers are aligning evidence, supply resilience, and integrated offerings to compete effectively

The competitive landscape for steroid injection products and services is defined by a mix of established pharmaceutical manufacturers, device providers that support procedural delivery, and specialty service organizations that offer site-of-care and training solutions. Leading manufacturers prioritize portfolio differentiation through formulation improvements, quality of supply, and demonstrated clinical safety. At the same time, device makers are innovating around delivery systems and image-guidance compatibility to improve procedural precision and workflow efficiency, creating opportunities for bundled offerings that address both drug and device needs.

Strategic imperatives among companies include strengthening supply chain resilience, investing in real-world evidence generation, and cultivating deeper relationships with key end users such as ambulatory surgical centers and specialty hospitals. Partnerships between pharmaceutical firms and device providers, as well as collaborations with health systems and payer groups, have emerged as practical routes to accelerate adoption and to align commercial models with a value-based focus. Competitive differentiation increasingly hinges on the ability to demonstrate meaningful clinical outcomes, to support training and credentialing for proceduralists, and to offer flexible distribution models that account for hospital pharmacies, retail pharmacies, and the growing role of digital procurement channels. Companies that integrate clinical evidence, operational support, and supply reliability are better positioned to meet stakeholder expectations and to drive adoption across care settings.

Actionable strategic priorities for manufacturers and providers to strengthen evidence generation, diversify supply chains, and create integrated therapeutic and delivery solutions

Industry leaders must adopt a proactive posture that aligns clinical evidence generation, supply chain strategy, and commercial execution to sustain long-term competitiveness in the steroid injection space. First, organizations should prioritize investment in real-world evidence programs and post-market studies that articulate comparative safety and functional outcomes across indications and delivery techniques. Such evidence supports formulary discussions, payer negotiations, and clinician adoption while also informing continuous product improvement.

Second, commercial and procurement teams should collaborate to implement diversified sourcing strategies and to evaluate regional manufacturing options that reduce exposure to trade-related disruptions and tariff volatility. Strengthening relationships with hospital pharmacies, ambulatory surgical centers, and clinic networks through tailored logistics solutions and flexible contracting will enhance supply continuity. Third, companies should develop integrated offerings that pair therapeutics with compatible delivery devices and training services, thereby reducing barriers to adoption and improving procedural outcomes. Finally, leaders should engage early with payers and regulatory bodies to align evidence generation with reimbursement requirements and to anticipate changes in coding or appropriate use criteria. By translating these recommendations into concrete programs and cross-functional plans, organizations can accelerate adoption, enhance patient outcomes, and fortify commercial resilience.

A transparent mixed-methods research approach combining clinician interviews, procurement insights, regulatory reviews, and literature synthesis to ensure robust conclusions

The research methodology underpinning this analysis integrates qualitative and quantitative techniques to build a comprehensive understanding of clinical practice, supply dynamics, and commercial drivers. Primary research included structured interviews with clinicians across specialties that routinely perform steroid injections, procurement leaders from hospitals and outpatient centers, and senior executives at manufacturing and distribution companies. These engagements provided first-hand insights into procedure volumes, clinical preferences for molecules and delivery methods, and operational challenges related to inventory and sourcing.

Secondary research encompassed regulatory filings, clinical guidelines, peer-reviewed literature on corticosteroid safety and efficacy, and public policy documents that affect trade and reimbursement. The analysis also incorporated trend synthesis from device registries and training program adoption metrics to understand the diffusion of image-guided procedures. Data triangulation across sources ensured that conclusions reflect consistent patterns rather than isolated observations. Where applicable, the methodology emphasized transparency in data provenance, a clear articulation of analytical assumptions, and sensitivity analyses to account for variability in practice patterns and supply chain configurations.

A conclusive synthesis emphasizing clinical value, supply resilience, and cross-functional strategies as determinants of future success in steroid injection care delivery

In conclusion, steroid injections remain a vital component of musculoskeletal and pain management practice, sustained by procedural innovation, targeted clinical application, and adaptable delivery models. Stakeholders face a landscape shaped by increasing emphasis on precision delivery, payer-driven evidence expectations, and supply chain pressures that may include trade-related cost variability. Strategic responses that emphasize robust real-world evidence, diversified sourcing, and integrated product-service offerings will be central to meeting clinician and institutional needs while preserving operational resilience.

Moving forward, the ability to translate clinical efficacy into demonstrable outcomes, to secure reliable and cost-effective supply channels, and to align commercial models with evolving reimbursement and regulatory requirements will determine competitive positioning. Cross-functional collaboration across clinical development, supply chain, and commercial teams is essential to convert insights into scalable programs that improve patient care and sustain organizational performance.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Steroid Injections Market, by Molecule Type

  • 8.1. Dexamethasone
  • 8.2. Hydrocortisone
  • 8.3. Methylprednisolone
  • 8.4. Triamcinolone

9. Steroid Injections Market, by Treatment Type

  • 9.1. Joint Injections
    • 9.1.1. Large Joints
    • 9.1.2. Small Joints
  • 9.2. Soft Tissue Injections
    • 9.2.1. Bursa Injections
    • 9.2.2. Ligament Injections
    • 9.2.3. Tendon Injections
  • 9.3. Spinal Injections
    • 9.3.1. Epidural
    • 9.3.2. Intrathecal

10. Steroid Injections Market, by Patient Type

  • 10.1. Adult
  • 10.2. Geriatric
  • 10.3. Pediatric

11. Steroid Injections Market, by Therapeutic Indication

  • 11.1. Back Pain
    • 11.1.1. Lower Back Pain
    • 11.1.2. Sciatica
    • 11.1.3. Upper Back Pain
  • 11.2. Bursitis
  • 11.3. Osteoarthritis
  • 11.4. Rheumatoid Arthritis
  • 11.5. Tendonitis

12. Steroid Injections Market, by End User

  • 12.1. Ambulatory Surgical Centers
  • 12.2. Clinics
  • 12.3. Hospitals
    • 12.3.1. General Hospitals
    • 12.3.2. Specialty Hospitals

13. Steroid Injections Market, by Distribution Channel

  • 13.1. Hospital Pharmacies
  • 13.2. Online Pharmacies
  • 13.3. Retail Pharmacies
    • 13.3.1. Chain Pharmacies
    • 13.3.2. Independent Pharmacies

14. Steroid Injections Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Steroid Injections Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Steroid Injections Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Steroid Injections Market

18. China Steroid Injections Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. AbbVie Inc.
  • 19.6. Bayer AG
  • 19.7. Bristol-Myers Squibb Company
  • 19.8. Johnson & Johnson
  • 19.9. Merck & Co., Inc.
  • 19.10. Novartis AG
  • 19.11. Pfizer Inc.
  • 19.12. Roche Holding AG
  • 19.13. Teva Pharmaceutical Industries Ltd.
  • 19.14. Viatris Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL STEROID INJECTIONS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL STEROID INJECTIONS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL STEROID INJECTIONS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL STEROID INJECTIONS MARKET SIZE, BY MOLECULE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL STEROID INJECTIONS MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL STEROID INJECTIONS MARKET SIZE, BY PATIENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL STEROID INJECTIONS MARKET SIZE, BY THERAPEUTIC INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL STEROID INJECTIONS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL STEROID INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL STEROID INJECTIONS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL STEROID INJECTIONS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL STEROID INJECTIONS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES STEROID INJECTIONS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA STEROID INJECTIONS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL STEROID INJECTIONS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL STEROID INJECTIONS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL STEROID INJECTIONS MARKET SIZE, BY DEXAMETHASONE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL STEROID INJECTIONS MARKET SIZE, BY DEXAMETHASONE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL STEROID INJECTIONS MARKET SIZE, BY DEXAMETHASONE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL STEROID INJECTIONS MARKET SIZE, BY HYDROCORTISONE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL STEROID INJECTIONS MARKET SIZE, BY HYDROCORTISONE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL STEROID INJECTIONS MARKET SIZE, BY HYDROCORTISONE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL STEROID INJECTIONS MARKET SIZE, BY METHYLPREDNISOLONE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL STEROID INJECTIONS MARKET SIZE, BY METHYLPREDNISOLONE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL STEROID INJECTIONS MARKET SIZE, BY METHYLPREDNISOLONE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL STEROID INJECTIONS MARKET SIZE, BY TRIAMCINOLONE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL STEROID INJECTIONS MARKET SIZE, BY TRIAMCINOLONE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL STEROID INJECTIONS MARKET SIZE, BY TRIAMCINOLONE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL STEROID INJECTIONS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL STEROID INJECTIONS MARKET SIZE, BY JOINT INJECTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL STEROID INJECTIONS MARKET SIZE, BY JOINT INJECTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL STEROID INJECTIONS MARKET SIZE, BY JOINT INJECTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL STEROID INJECTIONS MARKET SIZE, BY JOINT INJECTIONS, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL STEROID INJECTIONS MARKET SIZE, BY LARGE JOINTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL STEROID INJECTIONS MARKET SIZE, BY LARGE JOINTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL STEROID INJECTIONS MARKET SIZE, BY LARGE JOINTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL STEROID INJECTIONS MARKET SIZE, BY SMALL JOINTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL STEROID INJECTIONS MARKET SIZE, BY SMALL JOINTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL STEROID INJECTIONS MARKET SIZE, BY SMALL JOINTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL STEROID INJECTIONS MARKET SIZE, BY SOFT TISSUE INJECTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL STEROID INJECTIONS MARKET SIZE, BY SOFT TISSUE INJECTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL STEROID INJECTIONS MARKET SIZE, BY SOFT TISSUE INJECTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL STEROID INJECTIONS MARKET SIZE, BY SOFT TISSUE INJECTIONS, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL STEROID INJECTIONS MARKET SIZE, BY BURSA INJECTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL STEROID INJECTIONS MARKET SIZE, BY BURSA INJECTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL STEROID INJECTIONS MARKET SIZE, BY BURSA INJECTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL STEROID INJECTIONS MARKET SIZE, BY LIGAMENT INJECTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL STEROID INJECTIONS MARKET SIZE, BY LIGAMENT INJECTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL STEROID INJECTIONS MARKET SIZE, BY LIGAMENT INJECTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL STEROID INJECTIONS MARKET SIZE, BY TENDON INJECTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL STEROID INJECTIONS MARKET SIZE, BY TENDON INJECTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL STEROID INJECTIONS MARKET SIZE, BY TENDON INJECTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL STEROID INJECTIONS MARKET SIZE, BY SPINAL INJECTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL STEROID INJECTIONS MARKET SIZE, BY SPINAL INJECTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL STEROID INJECTIONS MARKET SIZE, BY SPINAL INJECTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL STEROID INJECTIONS MARKET SIZE, BY SPINAL INJECTIONS, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL STEROID INJECTIONS MARKET SIZE, BY EPIDURAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL STEROID INJECTIONS MARKET SIZE, BY EPIDURAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL STEROID INJECTIONS MARKET SIZE, BY EPIDURAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL STEROID INJECTIONS MARKET SIZE, BY INTRATHECAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL STEROID INJECTIONS MARKET SIZE, BY INTRATHECAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL STEROID INJECTIONS MARKET SIZE, BY INTRATHECAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL STEROID INJECTIONS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL STEROID INJECTIONS MARKET SIZE, BY ADULT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL STEROID INJECTIONS MARKET SIZE, BY ADULT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL STEROID INJECTIONS MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL STEROID INJECTIONS MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL STEROID INJECTIONS MARKET SIZE, BY GERIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL STEROID INJECTIONS MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL STEROID INJECTIONS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL STEROID INJECTIONS MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL STEROID INJECTIONS MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL STEROID INJECTIONS MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL STEROID INJECTIONS MARKET SIZE, BY BACK PAIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL STEROID INJECTIONS MARKET SIZE, BY BACK PAIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL STEROID INJECTIONS MARKET SIZE, BY BACK PAIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL STEROID INJECTIONS MARKET SIZE, BY BACK PAIN, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL STEROID INJECTIONS MARKET SIZE, BY LOWER BACK PAIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL STEROID INJECTIONS MARKET SIZE, BY LOWER BACK PAIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL STEROID INJECTIONS MARKET SIZE, BY LOWER BACK PAIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL STEROID INJECTIONS MARKET SIZE, BY SCIATICA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL STEROID INJECTIONS MARKET SIZE, BY SCIATICA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL STEROID INJECTIONS MARKET SIZE, BY SCIATICA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL STEROID INJECTIONS MARKET SIZE, BY UPPER BACK PAIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL STEROID INJECTIONS MARKET SIZE, BY UPPER BACK PAIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL STEROID INJECTIONS MARKET SIZE, BY UPPER BACK PAIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL STEROID INJECTIONS MARKET SIZE, BY BURSITIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL STEROID INJECTIONS MARKET SIZE, BY BURSITIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL STEROID INJECTIONS MARKET SIZE, BY BURSITIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL STEROID INJECTIONS MARKET SIZE, BY OSTEOARTHRITIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL STEROID INJECTIONS MARKET SIZE, BY OSTEOARTHRITIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL STEROID INJECTIONS MARKET SIZE, BY OSTEOARTHRITIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL STEROID INJECTIONS MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL STEROID INJECTIONS MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL STEROID INJECTIONS MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL STEROID INJECTIONS MARKET SIZE, BY TENDONITIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL STEROID INJECTIONS MARKET SIZE, BY TENDONITIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL STEROID INJECTIONS MARKET SIZE, BY TENDONITIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL STEROID INJECTIONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL STEROID INJECTIONS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL STEROID INJECTIONS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL STEROID INJECTIONS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL STEROID INJECTIONS MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL STEROID INJECTIONS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL STEROID INJECTIONS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL STEROID INJECTIONS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL STEROID INJECTIONS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL STEROID INJECTIONS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL STEROID INJECTIONS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL STEROID INJECTIONS MARKET SIZE, BY GENERAL HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL STEROID INJECTIONS MARKET SIZE, BY GENERAL HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL STEROID INJECTIONS MARKET SIZE, BY GENERAL HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL STEROID INJECTIONS MARKET SIZE, BY SPECIALTY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL STEROID INJECTIONS MARKET SIZE, BY SPECIALTY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL STEROID INJECTIONS MARKET SIZE, BY SPECIALTY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL STEROID INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL STEROID INJECTIONS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL STEROID INJECTIONS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL STEROID INJECTIONS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL STEROID INJECTIONS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL STEROID INJECTIONS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL STEROID INJECTIONS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL STEROID INJECTIONS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL STEROID INJECTIONS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL STEROID INJECTIONS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL STEROID INJECTIONS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL STEROID INJECTIONS MARKET SIZE, BY CHAIN PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL STEROID INJECTIONS MARKET SIZE, BY CHAIN PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL STEROID INJECTIONS MARKET SIZE, BY CHAIN PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL STEROID INJECTIONS MARKET SIZE, BY INDEPENDENT PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL STEROID INJECTIONS MARKET SIZE, BY INDEPENDENT PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL STEROID INJECTIONS MARKET SIZE, BY INDEPENDENT PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL STEROID INJECTIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 120. AMERICAS STEROID INJECTIONS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 121. AMERICAS STEROID INJECTIONS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. AMERICAS STEROID INJECTIONS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 123. AMERICAS STEROID INJECTIONS MARKET SIZE, BY JOINT INJECTIONS, 2018-2032 (USD MILLION)
  • TABLE 124. AMERICAS STEROID INJECTIONS MARKET SIZE, BY SOFT TISSUE INJECTIONS, 2018-2032 (USD MILLION)
  • TABLE 125. AMERICAS STEROID INJECTIONS MARKET SIZE, BY SPINAL INJECTIONS, 2018-2032 (USD MILLION)
  • TABLE 126. AMERICAS STEROID INJECTIONS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. AMERICAS STEROID INJECTIONS MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2032 (USD MILLION)
  • TABLE 128. AMERICAS STEROID INJECTIONS MARKET SIZE, BY BACK PAIN, 2018-2032 (USD MILLION)
  • TABLE 129. AMERICAS STEROID INJECTIONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 130. AMERICAS STEROID INJECTIONS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 131. AMERICAS STEROID INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 132. AMERICAS STEROID INJECTIONS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 133. NORTH AMERICA STEROID INJECTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 134. NORTH AMERICA STEROID INJECTIONS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 135. NORTH AMERICA STEROID INJECTIONS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 136. NORTH AMERICA STEROID INJECTIONS MARKET SIZE, BY JOINT INJECTIONS, 2018-2032 (USD MILLION)
  • TABLE 137. NORTH AMERICA STEROID INJECTIONS MARKET SIZE, BY SOFT TISSUE INJECTIONS, 2018-2032 (USD MILLION)
  • TABLE 138. NORTH AMERICA STEROID INJECTIONS MARKET SIZE, BY SPINAL INJECTIONS, 2018-2032 (USD MILLION)
  • TABLE 139. NORTH AMERICA STEROID INJECTIONS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 140. NORTH AMERICA STEROID INJECTIONS MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2032 (USD MILLION)
  • TABLE 141. NORTH AMERICA STEROID INJECTIONS MARKET SIZE, BY BACK PAIN, 2018-2032 (USD MILLION)
  • TABLE 142. NORTH AMERICA STEROID INJECTIONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 143. NORTH AMERICA STEROID INJECTIONS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 144. NORTH AMERICA STEROID INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 145. NORTH AMERICA STEROID INJECTIONS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 146. LATIN AMERICA STEROID INJECTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. LATIN AMERICA STEROID INJECTIONS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 148. LATIN AMERICA STEROID INJECTIONS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 149. LATIN AMERICA STEROID INJECTIONS MARKET SIZE, BY JOINT INJECTIONS, 2018-2032 (USD MILLION)
  • TABLE 150. LATIN AMERICA STEROID INJECTIONS MARKET SIZE, BY SOFT TISSUE INJECTIONS, 2018-2032 (USD MILLION)
  • TABLE 151. LATIN AMERICA STEROID INJECTIONS MARKET SIZE, BY SPINAL INJECTIONS, 2018-2032 (USD MILLION)
  • TABLE 152. LATIN AMERICA STEROID INJECTIONS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 153. LATIN AMERICA STEROID INJECTIONS MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2032 (USD MILLION)
  • TABLE 154. LATIN AMERICA STEROID INJECTIONS MARKET SIZE, BY BACK PAIN, 2018-2032 (USD MILLION)
  • TABLE 155. LATIN AMERICA STEROID INJECTIONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 156. LATIN AMERICA STEROID INJECTIONS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 157. LATIN AMERICA STEROID INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 158. LATIN AMERICA STEROID INJECTIONS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPE, MIDDLE EAST & AFRICA STEROID INJECTIONS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPE, MIDDLE EAST & AFRICA STEROID INJECTIONS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPE, MIDDLE EAST & AFRICA STEROID INJECTIONS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPE, MIDDLE EAST & AFRICA STEROID INJECTIONS MARKET SIZE, BY JOINT INJECTIONS, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPE, MIDDLE EAST & AFRICA STEROID INJECTIONS MARKET SIZE, BY SOFT TISSUE INJECTIONS, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPE, MIDDLE EAST & AFRICA STEROID INJECTIONS MARKET SIZE, BY SPINAL INJECTIONS, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPE, MIDDLE EAST & AFRICA STEROID INJECTIONS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPE, MIDDLE EAST & AFRICA STEROID INJECTIONS MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPE, MIDDLE EAST & AFRICA STEROID INJECTIONS MARKET SIZE, BY BACK PAIN, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPE, MIDDLE EAST & AFRICA STEROID INJECTIONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPE, MIDDLE EAST & AFRICA STEROID INJECTIONS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPE, MIDDLE EAST & AFRICA STEROID INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPE, MIDDLE EAST & AFRICA STEROID INJECTIONS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPE STEROID INJECTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPE STEROID INJECTIONS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPE STEROID INJECTIONS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPE STEROID INJECTIONS MARKET SIZE, BY JOINT INJECTIONS, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPE STEROID INJECTIONS MARKET SIZE, BY SOFT TISSUE INJECTIONS, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPE STEROID INJECTIONS MARKET SIZE, BY SPINAL INJECTIONS, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPE STEROID INJECTIONS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPE STEROID INJECTIONS MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPE STEROID INJECTIONS MARKET SIZE, BY BACK PAIN, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPE STEROID INJECTIONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPE STEROID INJECTIONS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPE STEROID INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPE STEROID INJECTIONS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 185. MIDDLE EAST STEROID INJECTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 186. MIDDLE EAST STEROID INJECTIONS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 187. MIDDLE EAST STEROID INJECTIONS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 188. MIDDLE EAST STEROID INJECTIONS MARKET SIZE, BY JOINT INJECTIONS, 2018-2032 (USD MILLION)
  • TABLE 189. MIDDLE EAST STEROID INJECTIONS MARKET SIZE, BY SOFT TISSUE INJECTIONS, 2018-2032 (USD MILLION)
  • TABLE 190. MIDDLE EAST STEROID INJECTIONS MARKET SIZE, BY SPINAL INJECTIONS, 2018-2032 (USD MILLION)
  • TABLE 191. MIDDLE EAST STEROID INJECTIONS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 192. MIDDLE EAST STEROID INJECTIONS MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2032 (USD MILLION)
  • TABLE 193. MIDDLE EAST STEROID INJECTIONS MARKET SIZE, BY BACK PAIN, 2018-2032 (USD MILLION)
  • TABLE 194. MIDDLE EAST STEROID INJECTIONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 195. MIDDLE EAST STEROID INJECTIONS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 196. MIDDLE EAST STEROID INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 197. MIDDLE EAST STEROID INJECTIONS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 198. AFRICA STEROID INJECTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 199. AFRICA STEROID INJECTIONS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 200. AFRICA STEROID INJECTIONS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 201. AFRICA STEROID INJECTIONS MARKET SIZE, BY JOINT INJECTIONS, 2018-2032 (USD MILLION)
  • TABLE 202. AFRICA STEROID INJECTIONS MARKET SIZE, BY SOFT TISSUE INJECTIONS, 2018-2032 (USD MILLION)
  • TABLE 203. AFRICA STEROID INJECTIONS MARKET SIZE, BY SPINAL INJECTIONS, 2018-2032 (USD MILLION)
  • TABLE 204. AFRICA STEROID INJECTIONS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 205. AFRICA STEROID INJECTIONS MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2032 (USD MILLION)
  • TABLE 206. AFRICA STEROID INJECTIONS MARKET SIZE, BY BACK PAIN, 2018-2032 (USD MILLION)
  • TABLE 207. AFRICA STEROID INJECTIONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 208. AFRICA STEROID INJECTIONS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 209. AFRICA STEROID INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 210. AFRICA STEROID INJECTIONS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 211. ASIA-PACIFIC STEROID INJECTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 212. ASIA-PACIFIC STEROID INJECTIONS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 213. ASIA-PACIFIC STEROID INJECTIONS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 214. ASIA-PACIFIC STEROID INJECTIONS MARKET SIZE, BY JOINT INJECTIONS, 2018-2032 (USD MILLION)
  • TABLE 215. ASIA-PACIFIC STEROID INJECTIONS MARKET SIZE, BY SOFT TISSUE INJECTIONS, 2018-2032 (USD MILLION)
  • TABLE 216. ASIA-PACIFIC STEROID INJECTIONS MARKET SIZE, BY SPINAL INJECTIONS, 2018-2032 (USD MILLION)
  • TABLE 217. ASIA-PACIFIC STEROID INJECTIONS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 218. ASIA-PACIFIC STEROID INJECTIONS MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2032 (USD MILLION)
  • TABLE 219. ASIA-PACIFIC STEROID INJECTIONS MARKET SIZE, BY BACK PAIN, 2018-2032 (USD MILLION)
  • TABLE 220. ASIA-PACIFIC STEROID INJECTIONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 221. ASIA-PACIFIC STEROID INJECTIONS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 222. ASIA-PACIFIC STEROID INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 223. ASIA-PACIFIC STEROID INJECTIONS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 224. GLOBAL STEROID INJECTIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 225. ASEAN STEROID INJECTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 226. ASEAN STEROID INJECTIONS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 227. ASEAN STEROID INJECTIONS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 228. ASEAN STEROID INJECTIONS MARKET SIZE, BY JOINT INJECTIONS, 2018-2032 (USD MILLION)
  • TABLE 229. ASEAN STEROID INJECTIONS MARKET SIZE, BY SOFT TISSUE INJECTIONS, 2018-2032 (USD MILLION)
  • TABLE 230. ASEAN STEROID INJECTIONS MARKET SIZE, BY SPINAL INJECTIONS, 2018-2032 (USD MILLION)
  • TABLE 231. ASEAN STEROID INJECTIONS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 232. ASEAN STEROID INJECTIONS MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2032 (USD MILLION)
  • TABLE 233. ASEAN STEROID INJECTIONS MARKET SIZE, BY BACK PAIN, 2018-2032 (USD MILLION)
  • TABLE 234. ASEAN STEROID INJECTIONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 235. ASEAN STEROID INJECTIONS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 236. ASEAN STEROID INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 237. ASEAN STEROID INJECTIONS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 238. GCC STEROID INJECTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 239. GCC STEROID INJECTIONS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 240. GCC STEROID INJECTIONS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 241. GCC STEROID INJECTIONS MARKET SIZE, BY JOINT INJECTIONS, 2018-2032 (USD MILLION)
  • TABLE 242. GCC STEROID INJECTIONS MARKET SIZE, BY SOFT TISSUE INJECTIONS, 2018-2032 (USD MILLION)
  • TABLE 243. GCC STEROID INJECTIONS MARKET SIZE, BY SPINAL INJECTIONS, 2018-2032 (USD MILLION)
  • TABLE 244. GCC STEROID INJECTIONS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 245. GCC STEROID INJECTIONS MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2032 (USD MILLION)
  • TABLE 246. GCC STEROID INJECTIONS MARKET SIZE, BY BACK PAIN, 2018-2032 (USD MILLION)
  • TABLE 247. GCC STEROID INJECTIONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 248. GCC STEROID INJECTIONS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 249. GCC STEROID INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 250. GCC STEROID INJECTIONS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 251. EUROPEAN UNION STEROID INJECTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 252. EUROPEAN UNION STEROID INJECTIONS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 253. EUROPEAN UNION STEROID INJECTIONS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 254. EUROPEAN UNION STEROID INJECTIONS MARKET SIZE, BY JOINT INJECTIONS, 2018-2032 (USD MILLION)
  • TABLE 255. EUROPEAN UNION STEROID INJECTIONS MARKET SIZE, BY SOFT TISSUE INJECTIONS, 2018-2032 (USD MILLION)
  • TABLE 256. EUROPEAN UNION STEROID INJECTIONS MARKET SIZE, BY SPINAL INJECTIONS, 2018-2032 (USD MILLION)
  • TABLE 257. EUROPEAN UNION STEROID INJECTIONS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 258. EUROPEAN UNION STEROID INJECTIONS MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2032 (USD MILLION)
  • TABLE 259. EUROPEAN UNION STEROID INJECTIONS MARKET SIZE, BY BACK PAIN, 2018-2032 (USD MILLION)
  • TABLE 260. EUROPEAN UNION STEROID INJECTIONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 261. EUROPEAN UNION STEROID INJECTIONS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 262. EUROPEAN UNION STEROID INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 263. EUROPEAN UNION STEROID INJECTIONS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 264. BRICS STEROID INJECTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 265. BRICS STEROID INJECTIONS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 266. BRICS STEROID INJECTIONS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 267. BRICS STEROID INJECTIONS MARKET SIZE, BY JOINT INJECTIONS, 2018-2032 (USD MILLION)
  • TABLE 268. BRICS STEROID INJECTIONS MARKET SIZE, BY SOFT TISSUE INJECTIONS, 2018-2032 (USD MILLION)
  • TABLE 269. BRICS STEROID INJECTIONS MARKET SIZE, BY SPINAL INJECTIONS, 2018-2032 (USD MILLION)
  • TABLE 270. BRICS STEROID INJECTIONS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 271. BRICS STEROID INJECTIONS MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2032 (USD MILLION)
  • TABLE 272. BRICS STEROID INJECTIONS MARKET SIZE, BY BACK PAIN, 2018-2032 (USD MILLION)
  • TABLE 273. BRICS STEROID INJECTIONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 274. BRICS STEROID INJECTIONS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 275. BRICS STEROID INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 276. BRICS STEROID INJECTIONS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 277. G7 STEROID INJECTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 278. G7 STEROID INJECTIONS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 279. G7 STEROID INJECTIONS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 280. G7 STEROID INJECTIONS MARKET SIZE, BY JOINT INJECTIONS, 2018-2032 (USD MILLION)
  • TABLE 281. G7 STEROID INJECTIONS MARKET SIZE, BY SOFT TISSUE INJECTIONS, 2018-2032 (USD MILLION)
  • TABLE 282. G7 STEROID INJECTIONS MARKET SIZE, BY SPINAL INJECTIONS, 2018-2032 (USD MILLION)
  • TABLE 283. G7 STEROID INJECTIONS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 284. G7 STEROID INJECTIONS MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2032 (USD MILLION)
  • TABLE 285. G7 STEROID INJECTIONS MARKET SIZE, BY BACK PAIN, 2018-2032 (USD MILLION)
  • TABLE 286. G7 STEROID INJECTIONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 287. G7 STEROID INJECTIONS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 288. G7 STEROID INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 289. G7 STEROID INJECTIONS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 290. NATO STEROID INJECTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 291. NATO STEROID INJECTIONS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 292. NATO STEROID INJECTIONS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 293. NATO STEROID INJECTIONS MARKET SIZE, BY JOINT INJECTIONS, 2018-2032 (USD MILLION)
  • TABLE 294. NATO STEROID INJECTIONS MARKET SIZE, BY SOFT TISSUE INJECTIONS, 2018-2032 (USD MILLION)
  • TABLE 295. NATO STEROID INJECTIONS MARKET SIZE, BY SPINAL INJECTIONS, 2018-2032 (USD MILLION)
  • TABLE 296. NATO STEROID INJECTIONS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 297. NATO STEROID INJECTIONS MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2032 (USD MILLION)
  • TABLE 298. NATO STEROID INJECTIONS MARKET SIZE, BY BACK PAIN, 2018-2032 (USD MILLION)
  • TABLE 299. NATO STEROID INJECTIONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 300. NATO STEROID INJECTIONS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 301. NATO STEROID INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 302. NATO STEROID INJECTIONS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 303. GLOBAL STEROID INJECTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 304. UNITED STATES STEROID INJECTIONS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 305. UNITED STATES STEROID INJECTIONS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 306. UNITED STATES STEROID INJECTIONS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 307. UNITED STATES STEROID INJECTIONS MARKET SIZE, BY JOINT INJECTIONS, 2018-2032 (USD MILLION)
  • TABLE 308. UNITED STATES STEROID INJECTIONS MARKET SIZE, BY SOFT TISSUE INJECTIONS, 2018-2032 (USD MILLION)
  • TABLE 309. UNITED STATES STEROID INJECTIONS MARKET SIZE, BY SPINAL INJECTIONS, 2018-2032 (USD MILLION)
  • TABLE 310. UNITED STATES STEROID INJECTIONS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 311. UNITED STATES STEROID INJECTIONS MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2032 (USD MILLION)
  • TABLE 312. UNITED STATES STEROID INJECTIONS MARKET SIZE, BY BACK PAIN, 2018-2032 (USD MILLION)
  • TABLE 313. UNITED STATES STEROID INJECTIONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 314. UNITED STATES STEROID INJECTIONS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 315. UNITED STATES STEROID INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 316. UNITED STATES STEROID INJECTIONS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 317. CHINA STEROID INJECTIONS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 318. CHINA STEROID INJECTIONS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 319. CHINA STEROID INJECTIONS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 320. CHINA STEROID INJECTIONS MARKET SIZE, BY JOINT INJECTIONS, 2018-2032 (USD MILLION)
  • TABLE 321. CHINA STEROID INJECTIONS MARKET SIZE, BY SOFT TISSUE INJECTIONS, 2018-2032 (USD MILLION)
  • TABLE 322. CHINA STEROID INJECTIONS MARKET SIZE, BY SPINAL INJECTIONS, 2018-2032 (USD MILLION)
  • TABLE 323. CHINA STEROID INJECTIONS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 324. CHINA STEROID INJECTIONS MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2032 (USD MILLION)
  • TABLE 325. CHINA STEROID INJECTIONS MARKET SIZE, BY BACK PAIN, 2018-2032 (USD MILLION)
  • TABLE 326. CHINA STEROID INJECTIONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 327. CHINA STEROID INJECTIONS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 328. CHINA STEROID INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 329. CHINA STEROID INJECTIONS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)